Effect of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamideantiviral Therapy on Renal Function in Chronic Hepatitis B Patients: A Real-World Retrospective Study

• Published in: International journal of general medicine Vol. 18; pp. 1143 - 1153
• Main Authors: Li, Yu, Li, Ya-Wei, Gao, Ying
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2025; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Analysis; Antigens; antiviral; Antiviral agents; Antiviral drugs; chronic hepatitis b; Chronic illnesses; Diabetes; Hepatitis B; Hospitals; Infections; Kidney diseases; linear mixed-effects model; Liver cancer; Liver cirrhosis; Liver diseases; Mortality; nucleos(t)ide analogs; Original Research; renal function; Software; Statistical analysis; Statistical significance; Telbivudine; Tenofovir; Toxicity; Type 2 diabetes; Urea; Variance analysis; Viruses; China; United States > US; chronic hepatitis B; renal function; linear mixed-effects model; nucleos(t)ide analogs; antiviral
• ISSN: 1178-7074; 1178-7074
• DOI: 10.2147/IJGM.S497550

Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide(TAF) are first-line nucleos(t)ide analogs (NUCs) with chronic hepatitis B (CHB). This study aimed to assess the renal safety profile in NUC-experienced CHB patients who received ETV, TDF or TAF therapy. This retrospective observational cohort study investigated factors related to renal function in 154 patients with NUC-experienced CHB who received ETV, TDF, and TAF therapy for 48 weeks. Changes in UREA, uric acid (UA), creatinine (Cr), and estimated glomerular filtration rate (eGFR) were analyzed using a one-way analysis of variance. A linear mixed-effects model for repeated measures was used to evaluate the correlation between baseline information and eGFR changes 48 weeks following treatment initiation. The model considered sex, baseline age, viral load, aminotransferases, renal function, and treatment group as fixed effects, and incorporated random effects for individual subjects. There were no significant differences in UA or Cr levels during therapy over time. The eGFR level was elevated in ETV-treated patients (117.5 ± 16.65 mL/min/1.7m vs 109.8 ± 15.69 mL/min/1.7m , =0.027), whereas it did not change significantly in TDF- (123.6 ± 28.54 mL/min/1.7m vs 115.5 ± 20.44 mL/min/1.7m , =0.070) and TAF-treated (121.6 ± 23.44 mL/min/1.7m vs 113.4 ± 16.90 mL/min/1.7m , =0.053) patients. Younger patients (<30 years) and those with higher HBV DNA (> 7 log IU/mL) and lower alanine aminotransferase levels (<5 × upper limit of normal) showed a significant improvement in eGFR elevation during NUCs therapy. The linear mixed-effects model showed that the baseline HBV DNA level was an important positive predictor of eGFR elevation at 48 weeks following treatment initiation (estimate was 1.437 and 2.449, <0.001). In real-life experience, ETV, TDF, and TAF therapy may not be associated with eGFR changes in NUC-experienced CHB patients without baseline renal impairment.